Loading
A phase 1/2 trial of TAS0953/HM06 in non-small-cell lung cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities is a phase 1/2 interventional study registered as NCT04683250 by Taiho Pharmaceutical Co., Ltd., with 244 participants planned, started 2020-12-16 and due to reach its primary completion in 2030-03. Interventions recorded: TAS0953/HM06.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Araris Biotech (Taiho), Non-small-cell lung cancer and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/